Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 12, 2014, Pages 1380-1384

  Martos, Maider ^a   Bujanda, Luis ^a   Salicio, Yolanda ^b   Sarasqueta, Cristina ^b   Ibarra, Begoña ^a   Mendarte, Usua ^a   Fernández Reyes, María ^b   Cosme, Angel ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

Author keywords

Clarithromycin; Culture; First line treatment; Helicobacter pylori; Resistance

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM CULTURE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THRUSH; UREA BREATH TEST; AGED; BREATH ANALYSIS; DRUG COMBINATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PREDICTIVE VALUE; REMISSION; SPAIN; TIME; TREATMENT OUTCOME;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BREATH TESTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OMEPRAZOLE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; REMISSION INDUCTION; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84927692923     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000197     Document Type: Article

References (19)

1. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus report. Gut 2012; 61:646-664.
2. Cosme A, Montes M, Martos M, Gil I, Mendarte U, Salicio Y, et al. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clin Microbiol Infect 2013; 19:379-383.
3. Perez-Trallero E, Montes M, Alcorta M, Zubillaga P, Telleria E. Nonendoscopic method to obtain Helicobacter pylori for culture. Lancet 1995; 345:622-623.
4. Perez-Trallero E, Montes M, Larrañaga M, Arenas JI. How long for the routine Helicobacter pylori antimicrobial susceptibility testing? The usefulness of the string test to obtain Helicobacter for culture. Am J Gastroenterol 1999; 94:3075-3076.
5. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Approved guideline, CLSI document M45-A2. Vol. 30, No. 18. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
6. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. Pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010; 19:409-414.
7. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Study Group Participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62:34-42.
8. Pérez-Trallero E, Ramírez-Lázaro MJ, Villar H, et al. Helicobacter pylori resistance to various antibiotics: multicenter Spanish study [in Spanish]. Gastroenterol Hepatol 2011; 34:236-237.
9. Megraud F, Kist M, López Brea M, Hirschl A, Andersen LP, Glupczynski Y, Hirschl A. Surveillance of Helicobacter pylori resistance to antibiotics in Europe 2008-2009. Gastroenterology 2011; 140 (Suppl 1):1715.
10. Maeda S, Yoshida H, Ogura K, Kanai F, Shiratori Y, Omata M. Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. Gut 1998; 10:317-321.
11. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59:1143-1153.
12. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28:868-877.
13. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147:553-562.
14. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105:65-73.
15. Gisbert JP, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44:313-325.
16. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2011; 34:604-617.
17. Mégraud F. H. Pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53:1374-1384.
18. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98:562-567.
19. Wenzhen Y, Yumin L, Quanlin G, Kehu Y, Lei J, Donghai W, Lijuan Y. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med 2010; 49:1103-1109.